149 related articles for article (PubMed ID: 36572783)
21. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
23. Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects.
Zhang X; Fettner S; Winter E; Masjedizadeh M; Hisoire G
Int J Clin Pharmacol Ther; 2011 Jun; 49(6):345-52. PubMed ID: 21612741
[TBL] [Abstract][Full Text] [Related]
24. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729
[TBL] [Abstract][Full Text] [Related]
25. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
[TBL] [Abstract][Full Text] [Related]
26. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Johnson TR; Tan W; Goulet L; Smith EB; Yamazaki S; Walker GS; O'Gorman MT; Bedarida G; Zou HY; Christensen JG; Nguyen LN; Shen Z; Dalvie D; Bello A; Smith BJ
Xenobiotica; 2015 Jan; 45(1):45-59. PubMed ID: 25034009
[TBL] [Abstract][Full Text] [Related]
27. Absorption, metabolism and excretion of [
Vuu I; Dahal UP; Wang Z; Shen X; Rodgers J; Wahlstrom J; Houk B
Cancer Chemother Pharmacol; 2022 Oct; 90(4):357-367. PubMed ID: 36063185
[TBL] [Abstract][Full Text] [Related]
28. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.
Hoffmann M; Kasserra C; Reyes J; Schafer P; Kosek J; Capone L; Parton A; Kim-Kang H; Surapaneni S; Kumar G
Cancer Chemother Pharmacol; 2013 Feb; 71(2):489-501. PubMed ID: 23203815
[TBL] [Abstract][Full Text] [Related]
29. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
30. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
31. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide.
Kurebayashi H; Betsui H; Ohno Y
Toxicol Sci; 2003 May; 73(1):17-25. PubMed ID: 12700409
[TBL] [Abstract][Full Text] [Related]
32. Metabolism, excretion and pharmacokinetics of [
Lam JL; Vaz A; Hee B; Liang Y; Yang X; Shaik MN
Xenobiotica; 2017 Dec; 47(12):1064-1076. PubMed ID: 27866461
[TBL] [Abstract][Full Text] [Related]
33. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
Hoffmann M; Kumar G; Schafer P; Cedzik D; Capone L; Fong KL; Gu Z; Heller D; Feng H; Surapaneni S; Laskin O; Wu A
Xenobiotica; 2011 Dec; 41(12):1063-75. PubMed ID: 21859393
[TBL] [Abstract][Full Text] [Related]
34. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, mass balance, and metabolism of [
Ma S; Wang X; Yan S; Miao L; Wan X; Ding D; Yu D; Diao X; Wang X; Zhang H
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38507062
[TBL] [Abstract][Full Text] [Related]
36. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
[TBL] [Abstract][Full Text] [Related]
37. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
38. Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.
Li F; Chin C; Wangsa J; Ho J
Drug Metab Dispos; 2012 Sep; 40(9):1723-35. PubMed ID: 22653299
[TBL] [Abstract][Full Text] [Related]
39. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
40. Metabolic disposition of [
Wang L; Guo L; Wang Y; Guo R; Xu Z; Gao Z; Xie L; Chen J; Chen Y; Liu Y; Zhang H; Bao L; Xu W; Zhu M; Shao F; Shu Y
Br J Clin Pharmacol; 2021 Mar; 87(3):1475-1485. PubMed ID: 32959915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
